Abstracts tagged "Crystal-induced arthritis"

Abstract Number: 1898 • ACR Convergence 2021
Risk of Major Adverse Cardiovascular Events in a Large Cohort of Patients with Acute Calcium Pyrophosphate Crystal Arthritis
Sara Tedeschi¹, Weixing Huang¹, Kazuki Yoshida¹ and Daniel Solomon², ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Newton, MA
Background/Purpose: Acute calcium pyrophosphate (CPP) crystal arthritis, also known as pseudogout, causes an acute inflammatory arthritis that shares clinical similarities with gout. We investigated the…
Abstract Number: 0580 • ACR Convergence 2021
Association Between Female Reproductive Factors and Gout: A Nationwide Population-based Cohort Study of 1 Million Postmenopausal Women
Yeonghee Eun¹, In Young Kim², Kyungdo Han³, Kyu Na Lee³, Dong-Yun Lee¹, Dong Wook Shin¹, Seonyoung Kang¹, Seulkee Lee¹, Hoon-Suk Cha¹, Eun-Mi Koh¹, Jaejoon Lee¹ and Hyungjin Kim¹, ¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ²National Police Hospital, Seoul, Republic of Korea, ³Soongsil University, Seoul, Republic of Korea
Background/Purpose: Previous studies have shown that the incidence and risk factors of gout differs according to sex. However, little research has been done on the…
Abstract Number: 0582 • ACR Convergence 2021
Altered Risk of Gout According to Change of Metabolic Parameters in Young Adults
Yeonghee Eun¹, In Young Kim², Kyungdo Han³, Seonyoung Kang¹, Seulkee Lee¹, Hoon-Suk Cha¹, Eun-Mi Koh¹, Hyungjin Kim¹ and Jaejoon Lee¹, ¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ²National Police Hospital, Seoul, Republic of Korea, ³Soongsil University, Seoul, Republic of Korea
Background/Purpose: Previous studies have shown a link between gout and metabolic syndrome (MetS). It is well known that lifestyle modifications such as weight reduction and…
Abstract Number: 0666 • ACR Convergence 2021
Process Mapping Gout Hospitalizations: A Deep Dive into an Avoidable Epidemic
Mark Russell¹, Benjamin Ellis², Benjamin Clarke¹, Deepak Nagra¹ and James Galloway³, ¹King's College London, London, United Kingdom, ²Imperial College Healthcare NHS Trust, London, United Kingdom, ³Kings College London, London, United Kingdom
Background/Purpose: Hospital admissions for gout flares have increased dramatically in recent years. Strategies to reduce hospitalizations and improve uptake of urate-lowering therapy (ULT) are needed.…
Abstract Number: 0667 • ACR Convergence 2021
Active Screening for Gout Permits Identifying a Larger Cardiovascular Population at High Mortality Risk
Silvia Ruiz-Simón¹, Irene Calabuig², Miguel Gómez-Garberí³ and MARIANO ANDRES⁴, ¹Universidad Miguel Hernández, Alicante, Spain, ²Hospital General Universitario de Alicante, Alicante, Spain, ³Hospital Universitario San Juan de Alicante, San Juan de Alicante, Spain, ⁴Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain
Background/Purpose: We have recently noted by active screening that about a third of gout cases in the cardiovascular population is not registered in records (Calabuig,…
Abstract Number: 0679 • ACR Convergence 2021
Cardiovascular Risk Associated with Treatment of Allopurinol and Benzbromarone in Patients with Gout
Yeonghee Eun, Seonyoung Kang, Seulkee Lee, Hyungjin Kim, Jaejoon Lee, Eun-Mi Koh and Hoon-Suk Cha, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
Background/Purpose: Previous studies have shown that cardiovascular risk is increased in patients with gout. There are many studies on the effect of uric acid lowering…
Abstract Number: 1095 • ACR Convergence 2021
Improved Arthrocentesis and Fluid Yield of the Non-Effusive Knee Using Pneumatic Compression
Ahsan Iqbal¹, Sumir Brahmbhatt¹, Maheswari Muruganandam², David Cisneros³, Adnan Kiani², Fatemeh Farshami⁴, Jaren Trost⁵, N. Suzanne Emil², Sharon Nunez¹ and Wilmer Sibbitt², ¹UNM, Albuquerque, NM, ²University of New Mexico, Albuquerque, NM, ³University of New Mexico School of Medicine, Albuquerque, NM, ⁴University of New Mexico, Albuquerque, MD, ⁵Optum, Albuquerque, NM
Background/Purpose: Arthrocentesis is critical for diagnosis and therapy of joint disease; however, it is very difficult to obtain diagnostic fluid from an arthritic but clinically…
Abstract Number: 0445 • ACR Convergence 2020
Dual-Energy CT in Gout Patients: Do All Color-Coded Lesions Actually Represent Monosodium Urate Crystals?
Sara Christiansen¹, Felix Müller², Mikkel Østergaard³, Ole Slot¹, Jakob Møller², Henrik Børgesen², Kasper Gosvig² and Lene Terslev⁴, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup., Glostrup, Denmark, ²Department of Radiology, Herlev and Gentofte Hospital, Herlev, Denmark, ³Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, ⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup., Copenhagen, Denmark
Background/Purpose: Dual-Energy CT (DECT) can acknowledge differences in tissue compositions and can color-code tissues with specific features including monosodium urate (MSU) crystals. However, when evaluating…
Abstract Number: 0661 • ACR Convergence 2020
Genomic Regions Jointly Associated with eGFR and Serum Urate: Implications for Shared Genetic Etiology of Hyperuricemia and Chronic Kidney Disease
Nick Sumpter¹, Alexa Lupi², Megan Leask³, Tony Merriman⁴, Ana Vazquez² and Richard Reynolds¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Michigan State University, East Lansing, MI, ³University of Otago, Dunedin, Otago, New Zealand, ⁴University of Otago, Dunedin, New Zealand
Background/Purpose: Gout and hyperuricemia (HU), serum urate (SU) > 6.8 mg/dL, often present in the context of chronic kidney disease. It has long been known…
Abstract Number: 0670 • ACR Convergence 2020
Risk Factors for Pseudogout: An Electronic Medical Record Case-Control Study
Sara Tedeschi¹, Kazuki Yoshida¹, Weixing Huang² and Daniel H. Solomon¹, ¹Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ²Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston
Background/Purpose: Prior studies of calcium pyrophosphate crystal deposition disease (CPPD) epidemiology either focused on the entire spectrum of CPPD or identified patients with its acute…
Abstract Number: 0676 • ACR Convergence 2020
Surveying Practicing Rheumatologists Regarding Gout Management and Barriers in Gout Care
Joshua Gavin¹, Yashswee KC², Evan Dombrosky³, Nehal Shah⁴ and Youssef Roman⁴, ¹Virginia Commonwealth University School of Medicine, Richmond, ²Virginia Commonwealth University School of Medicine, Henrico, VA, ³Virginia Commonwealth University School of Medicine, Glen Allen, VA, ⁴Virginia Commonwealth University School of Medicine, Richmond, VA
Background/Purpose: The management of gout is heterogeneous across specialties and clinical settings. Gout has been demonstrated to be one of the most poorly managed conditions…
Abstract Number: 0685 • ACR Convergence 2020
The Impact of Azathioprine on the Frequency of Persistent Responsiveness to Pegloticase in Patients with Chronic Refractory Gout
Herbert S. Baraf¹, Hope Rainey², Peter Lipsky² and Peter Lipsky³, ¹The Ctr for Rheumatology and Bone Research, Wheaton, MD, ²AMPEL BioSolutions LLC., Charlottesville, VA, ³RILITE Foundation, Charlottesville, VA
Background/Purpose: Pegloticase is a mammalian recombinant uricase coupled to monomethoxy polyethylene glycol that is approved in the US for treatment of patients with chronic refractory…
Abstract Number: 0687 • ACR Convergence 2020
Musculoskeletal Manifestations in Patients with CD73 Deficiency
Cornelia Cudrici¹, Kam Newman², Deepak Lakshmipathy¹, Elisa Ferrante¹, Rebecca Huffstutler¹, Katherine Carney¹, Blas Betancourt², Markku Miettinen³, James Katz⁴, Leon Nesti⁵, Han Wen¹, Manfred Boehm⁶ and Alessandra Brofferio¹, ¹National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³National Cancer Institute, National Institutes of Health, Bethesda, MD, ⁴NIH NIAMS, Bethesda, MD, ⁵Clinical and Experimental Orthopaedics, Walter Reed National Military Medical Center, Bethesda, MD, ⁶Center for Molecular Medicine, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: Arterial calcification due to deficiency of CD73 (ACDC) is a hereditary autosomal recessive ectopic mineralization syndrome caused by loss-of-function mutations in the 5'-nucleotidase Ecto…
Abstract Number: 1573 • ACR Convergence 2020
Gout as an Immune-Related Adverse Event from Immune Checkpoint Inhibitors
Kevin Lee¹, Carrie Ye² and Shokrollah Elahi³, ¹Internal Medicine, University of Alberta, Edmonton, AB, Canada, ²Rheumatology, University of Alberta, Edmonton, AB, Canada, ³Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Immune checkpoint inhibitors (ICI) are novel treatments approved for various tumours including melanoma, lung and kidney. By interacting with immunoregulatory molecules (programmed death-1 (PD-1),…
Abstract Number: 343 • 2019 ACR/ARP Annual Meeting
Emergency Department Length of Stay in Patients with Acute Gout
Nadine Mbuyi¹, Steven Reinert ², Ross Hilliard ³, Anthony Reginato ³ and Deepan Dalal ³, ¹George Washington University, Washington, DC, ²Lifespan Health System, Providence, RI, ³Brown University, Rhode Island Hospital, Providence, RI
Background/Purpose: Emergency department (ED) visits for acute gout increased by approximately 20% between 2006 and 2014 in the United States. (1) Reducing ED length of stay…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].